Author Of 1 Presentation
INTRATRACHEAL ADMINISTRATION OF BUDESONIDE WITH SURFACTANT IN PRETERM INFANTS
Abstract
Background
Bronchopulmonary dysplasia (BPD) is one of the most fatal respiratory complication of preterm infants. Anti-inflammatory therapy with corticosteroid is the most effective treatment to prevent BPD. Intratracheal instillation of corticosteroid as new route of drug delivery has been studied to improve the local effect and to decrease the systemic side effect of steroid.
Objectives
We analyzed the effect of early intratracheal instillation of budesonide with surfactant to prevent BPD in very low birth weight preterm infants.
Methods
Very low birth weight infants diagnosed with severe respiratory distress syndrome were enrolled. Severe respiratory distress syndrome was diagnosed as chest radiography and requiring mechanical ventilator with fractional inspired oxygen (FiO2) of > 0.5. Treatment group were given budesonide and surfactant and control group were given surfactant.
Results
There were no differences in gestational age and body weight between two groups. Five vs 4 infants needed 2nd dose of surfactant in treatment group vs control group. One infant vs 4 infants were dead in treatment group vs in control group. Survival without BPD were 5 vs 3 in treatment group vs control group. Mild BPD and moderate BPD were 2, 2 vs 1, 2 in treatment group vs in control group. Invasive ventilation duration was 8 days vs 15.9 days in treatment group vs control group. Non-invasive ventilation such as SNIPPV or NCPAP duration was 4.7 days vs 10.7 days in treatment group vs control group.
Conclusion
Intratracheal administration budesonide with surfactant shortly after birth may prevent BPD and improve neonatal outcome.
Presenter of 1 Presentation
INTRATRACHEAL ADMINISTRATION OF BUDESONIDE WITH SURFACTANT IN PRETERM INFANTS
Abstract
Background
Bronchopulmonary dysplasia (BPD) is one of the most fatal respiratory complication of preterm infants. Anti-inflammatory therapy with corticosteroid is the most effective treatment to prevent BPD. Intratracheal instillation of corticosteroid as new route of drug delivery has been studied to improve the local effect and to decrease the systemic side effect of steroid.
Objectives
We analyzed the effect of early intratracheal instillation of budesonide with surfactant to prevent BPD in very low birth weight preterm infants.
Methods
Very low birth weight infants diagnosed with severe respiratory distress syndrome were enrolled. Severe respiratory distress syndrome was diagnosed as chest radiography and requiring mechanical ventilator with fractional inspired oxygen (FiO2) of > 0.5. Treatment group were given budesonide and surfactant and control group were given surfactant.
Results
There were no differences in gestational age and body weight between two groups. Five vs 4 infants needed 2nd dose of surfactant in treatment group vs control group. One infant vs 4 infants were dead in treatment group vs in control group. Survival without BPD were 5 vs 3 in treatment group vs control group. Mild BPD and moderate BPD were 2, 2 vs 1, 2 in treatment group vs in control group. Invasive ventilation duration was 8 days vs 15.9 days in treatment group vs control group. Non-invasive ventilation such as SNIPPV or NCPAP duration was 4.7 days vs 10.7 days in treatment group vs control group.
Conclusion
Intratracheal administration budesonide with surfactant shortly after birth may prevent BPD and improve neonatal outcome.